133 related articles for article (PubMed ID: 30199253)
1. Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.
Laghezza A; Piemontese L; Cerchia C; Montanari R; Capelli D; Giudici M; Crestani M; Tortorella P; Peiretti F; Pochetti G; Lavecchia A; Loiodice F
J Med Chem; 2018 Sep; 61(18):8282-8298. PubMed ID: 30199253
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Choi JH; Banks AS; Kamenecka TM; Busby SA; Chalmers MJ; Kumar N; Kuruvilla DS; Shin Y; He Y; Bruning JB; Marciano DP; Cameron MD; Laznik D; Jurczak MJ; Schürer SC; Vidović D; Shulman GI; Spiegelman BM; Griffin PR
Nature; 2011 Sep; 477(7365):477-81. PubMed ID: 21892191
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
Kim NJ; Lee KO; Koo BW; Li F; Yoo JK; Park HJ; Min KH; Lim JI; Kim MK; Kim JK; Suh YG
Bioorg Med Chem Lett; 2007 Jul; 17(13):3595-8. PubMed ID: 17507225
[TBL] [Abstract][Full Text] [Related]
4. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of phytocannabinoids as novel dual PPARα/γ agonists by a computational and in vitro experimental approach.
D'Aniello E; Fellous T; Iannotti FA; Gentile A; Allarà M; Balestrieri F; Gray R; Amodeo P; Vitale RM; Di Marzo V
Biochim Biophys Acta Gen Subj; 2019 Mar; 1863(3):586-597. PubMed ID: 30611848
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.
Fracchiolla G; Lavecchia A; Laghezza A; Piemontese L; Trisolini R; Carbonara G; Tortorella P; Novellino E; Loiodice F
Bioorg Med Chem; 2008 Nov; 16(21):9498-510. PubMed ID: 18835719
[TBL] [Abstract][Full Text] [Related]
7. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
[TBL] [Abstract][Full Text] [Related]
8. New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
Laghezza A; Pochetti G; Lavecchia A; Fracchiolla G; Faliti S; Piemontese L; Di Giovanni C; Iacobazzi V; Infantino V; Montanari R; Capelli D; Tortorella P; Loiodice F
J Med Chem; 2013 Jan; 56(1):60-72. PubMed ID: 23171045
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ.
Ahn S; Jang DM; Park SC; An S; Shin J; Han BW; Noh M
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054125
[TBL] [Abstract][Full Text] [Related]
10. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
[TBL] [Abstract][Full Text] [Related]
11. Screening of medicinal plants for PPARα and PPARγ activation and evaluation of their effects on glucose uptake and 3T3-L1 adipogenesis.
Yang MH; Avula B; Smillie T; Khan IA; Khan SI
Planta Med; 2013 Aug; 79(12):1084-95. PubMed ID: 23877921
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
[TBL] [Abstract][Full Text] [Related]
13. WSF-7 Inhibits Obesity-Mediated PPARγ Phosphorylation and Improves Insulin Sensitivity in 3T3-L1 Adipocytes.
Zhang Y; Wang Y; Li X; Gu K; Li M; Zhang Y; Zhang Z; Wang S; Li Z
Biol Pharm Bull; 2020; 43(3):526-532. PubMed ID: 32115511
[TBL] [Abstract][Full Text] [Related]
14. Constituents from Terminalia species increase PPARα and PPARγ levels and stimulate glucose uptake without enhancing adipocyte differentiation.
Yang MH; Vasquez Y; Ali Z; Khan IA; Khan SI
J Ethnopharmacol; 2013 Sep; 149(2):490-8. PubMed ID: 23850833
[TBL] [Abstract][Full Text] [Related]
15. Development of an ELISA for High-Throughput Screening of Inhibitors of Cdk5-Mediated PPARγ Phosphorylation.
Prokoph N; Ormö M; O'Mahony G; Hogner A; McPheat J; Karlsson U; Holmberg Schiavone L; Liu J
Assay Drug Dev Technol; 2016 May; 14(4):261-72. PubMed ID: 27027223
[TBL] [Abstract][Full Text] [Related]
16. Phloretin and phloridzin improve insulin sensitivity and enhance glucose uptake by subverting PPARγ/Cdk5 interaction in differentiated adipocytes.
Kumar S; Sinha K; Sharma R; Purohit R; Padwad Y
Exp Cell Res; 2019 Oct; 383(1):111480. PubMed ID: 31279631
[TBL] [Abstract][Full Text] [Related]
17. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
Mourad AAE; Mourad MAE
Life Sci; 2020 Oct; 259():118270. PubMed ID: 32814067
[TBL] [Abstract][Full Text] [Related]
18. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
[TBL] [Abstract][Full Text] [Related]
20. Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition.
Hanke T; Lamers C; Gomez RC; Schneider G; Werz O; Schubert-Zsilavecz M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3757-63. PubMed ID: 25037914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
